Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05379985 · ClinicalTrials.gov registry record · Phase 1

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

A Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC), sponsored by Revolution Medicines.

Recruiting
Registry status
Phase 1
Development phase
754
Enrollment target
16
Study locations

NCT05379985 is a Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 754 participants, above the 193-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (291% higher). The trial reports 16 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05379985, a Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by Revolution Medicines.

RECRUITING
Registry status
Phase 1
Development phase
754 participants
Enrollment target
16
Study locations

Study Summary

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Conditions Studied

Advanced Solid Tumors Non-small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • DRUG RMC-6236

Study Locations (16)

Texas

  • University of Texas at Austin - Austin
  • Mary Crowley Cancer Research - Dallas
  • The University of Texas MD Anderson Cancer Center - Houston
  • Next Oncology - San Antonio

New York

  • Perlmutter Cancer Center at NYU Langone Health - New York
  • Memorial Sloan-Kettering Cancer Center - New York
  • Columbia University - New York

California

  • UC Irvine/Chao Family Comprehensive Cancer Center - Orange
  • UCLA - Santa Monica

Florida

  • Moffitt Cancer Center - Tampa

Maryland

  • Johns Hopkins University - Baltimore

Massachusetts

  • Dana Farber Cancer Institute - Boston

Ohio

  • Christ Hospital Cancer Center - Cincinnati

Tennessee

  • Sarah Cannon Research Institute - Nashville

Trial Details

FieldValue
Enrollment Target 754 participants
Start Date 2022-05-31
Est. Completion 2027-07-26
Phase Phase 1

Sponsor

Revolution Medicines

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05379985

The ClinicalTrials.gov registry entry for NCT05379985 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 754 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 193-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (291% higher). The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which RMC-6236 is the first listed.

NCT05379985 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Texas, New York, California.

Frequently Asked Questions

What is clinical trial NCT05379985 about?

NCT05379985 is a clinical study titled "Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS". Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

What is the current status of trial NCT05379985?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 754 participants. The study started on 2022-05-31. Estimated completion is 2027-07-26.

What conditions does trial NCT05379985 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC).

What interventions are being tested in trial NCT05379985?

The interventions under investigation include: RMC-6236 (DRUG).

Who is sponsoring clinical trial NCT05379985?

This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05379985 being conducted?

This trial has 16 study locations across California, Florida, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.